Dyne Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €655.45M +130.2% -€47.92M -83.5% -7.3% +0.95 pp -€120.76M -73.8% -18.4% +1.4 pp
    (estimated) €284.74M +303.8% -€290.49M -28.1% -102.0% +4.7 pp -€460.62M +80.4% -161.8% +2.0 pp
    (estimated) €70.51M +8,074.0% -€403.95M -7.0% -572.9% +500 pp -€255.33M +12.3% -362.1% +260 pp
    (estimated) €862.59K +∞% -€434.36M +10.7% -50,355.0% -500 pp -€227.29M +25.5% -26,350.0% -260 pp
    (estimated) €0.00 +NaN% -€392.40M +43.3% N/A -€181.14M -27.6% N/A
    €0.00 +NaN% -€273.80M +34.5% N/A -€250.14M +54.7% N/A
    €0.00 +NaN% -€203.52M +42.8% N/A -€161.67M +24.5% N/A
    €0.00 +NaN% -€142.53M +10.7% N/A -€129.89M +29.9% N/A
    €0.00 +NaN% -€128.77M +154.2% N/A -€100.01M +155.7% N/A
    €0.00 +NaN% -€50.67M +333.9% N/A -€39.12M +345.1% N/A
    €0.00 +NaN% -€11.68M +181.4% N/A -€8.79M +152.8% N/A
    €0.00 -100.0% -€4.15M -106.3% N/A -€3.48M -100.5% N/A
    €436.47M -63.0% €65.56M -106.1% 15.0% +1.1 pp €697.83M -19.3% 159.9% +0.87 pp
    €1.18B +62.2% -€1.07B -2,580.0% -90.8% -0.97 pp €864.31M +171.5% 73.4% +0.30 pp
    €726.30M -42.6% €43.13M -174.6% 5.9% +0.11 pp €318.30M -695.2% 43.8% +0.48 pp
    €1.26B +48,766.7% -€57.79M -81.2% -4.6% +120 pp -€53.48M -122.7% -4.2% -91 pp
    €2.59M +0.0% -€307.08M -509.2% -11,866.7% -150 pp €235.49M -720.5% 9,100.0% +110 pp
    €2.59M -99.8% €75.05M -105.3% 2,900.0% +30 pp -€37.95M -119.8% -1,466.7% -15 pp
    €1.37B -31.8% -€1.42B +603.0% -103.8% -0.94 pp €191.49M -70.6% 14.0% -0.19 pp
    €2.00B -5.9% -€201.85M -81.5% -10.1% +0.41 pp €652.12M +460.0% 32.5% +0.27 pp
    €2.13B -30.5% -€1.09B -825.3% -51.1% -0.56 pp €116.45M -57.7% 5.5% -0.035 pp
    €3.06B +14.4% €150.09M -34.1% 4.9% -0.036 pp €275.17M -6.5% 9.0% -0.020 pp
    €2.68B €227.72M 8.5% €294.14M 11.0%

    Notifications